Principles of the therapeutic use of monoclonal antibodies in oncology.
Monoclonal antibodies have reached the stage of therapeutic agents, mostly in oncology, as illustrated by their wide use in lymphoma, breast cancer or colorectal cancer. The unravelling of their mechanisms of action and their interactions with their cellular receptors allows us to engineer new classes of therapeutic antibodies with increased efficacy. The identification of some of the tumour escape mechanisms may also help to define new approaches for patient selection and immunomonitoring. The present review addresses these various aspects.
Fridman
Wolf H
WH
INSERM U255, IFR des Cordeliers, Universités Paris-5 & Paris-6 et Hôpital Européen Georges-Pompidou, AP-HP, Paris, 15, rue de l'Ecole-de-Médecine, 75006 Paris, France. herve.fridman@u255.bhdc.jussieu.fr
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D008495:Medical Oncology / Q000639:trends; D008954:Models, Biological; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
D000911:Antibodies, Monoclonal